Full history for every metric is available with a Kvantra account
Allakos Inc. (ALLK)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Operating profit | $m | -122 | -76 | |||||
| Net profit | $m | -85 | -153 | -270 | -320 | -186 | -116 | -71 |
| EPS reported | $ | -1.30 | -0.80 | |||||
| Operating cashflow per share | $ | -1.05 | -1.05 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -1.06 | -1.06 | |||||
| Free cash flow | $m | -94 | -90 | |||||
| Net debt | $m | -81 | -55 | |||||
| Book value equity | $m | 79 | 55 | |||||
| Book value per share | $ | 0.89 | 0.62 | |||||
| Number of shares | m | 88.79 | 89.9 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.36 | 0.54 | |||||
| P/S LTM | x | 0.00 | 7.65 | |||||
| P/FCF LTM | x | -1.15 | -0.33 | |||||
| EV/EBITDA LTM | x | -0.87 | 0.30 | |||||
| EV/Sales LTM | x | 0.00 | -6.55 | |||||
| Earnings Yield LTM | % | -107.80% | -396.35% | |||||
| FCF Yield | % | -87.25% | -301.54% | |||||
| Quality | ||||||||
| ROE | % | -146.95% | -93.54% | |||||
| ROIC | % | -147.30% | -147.30% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | -63.83% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -22.55 | - | |||||
| Net Debt/EBITDA | x | 0.13 | 0.13 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -75.23% | -185.71% | |||||
| Net debt/Equity | x | -1.03 | -1.00 | |||||
| Gross debt/equity | x | 0.05 | 0.00 | |||||
Company overview
Allakos Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapeutic agents. These treatments are designed to target specific immunomodulatory receptors on immune effector cells, addressing a spectrum of allergic, inflammatory, and proliferative conditions. The company's flagship investigational product is lirentelimab (AK002), a monoclonal antibody. This compound is currently undergoing a pivotal Phase III clinical trial for eosinophilic gastritis and/or duodenitis. It is also being evaluated in a Phase II/III study for eosinophilic esophagitis, and a Phase II trial for atopic dermatitis and chronic spontaneous urticaria. Furthermore, Allakos is exploring lirentelimab (AK002) for potential use in mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. In parallel, their pipeline includes AK006, another candidate being developed to tackle various allergic and inflammatory diseases. Established in 2012, Allakos Inc. operates from its headquarters located in Redwood City, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Allakos Inc. (ALLK)
Allakos Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapeutic agents. These treatments are designed to target specific immunomodulatory receptors on immune effector cells, addressing a spectrum of allergic, inflammatory, and proliferative conditions. The company's flagship investigational product is lirentelimab (AK002), a monoclonal antibody. This compound is currently undergoing a pivotal Phase III clinical trial for eosinophilic gastritis and/or duodenitis. It is also being evaluated in a Phase II/III study for eosinophilic esophagitis, and a Phase II trial for atopic dermatitis and chronic spontaneous urticaria. Furthermore, Allakos is exploring lirentelimab (AK002) for potential use in mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. In parallel, their pipeline includes AK006, another candidate being developed to tackle various allergic and inflammatory diseases. Established in 2012, Allakos Inc. operates from its headquarters located in Redwood City, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free